These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2899140)

  • 1. Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia.
    Shimoyama M; Ota K; Kikuchi M; Yunoki K; Konda S; Takatsuki K; Ichimaru M; Tominaga S; Tsugane S; Minato K
    J Clin Oncol; 1988 Jul; 6(7):1088-97. PubMed ID: 2899140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M.
    Shimoyama M; Ota K; Kikuchi M; Yunoki K; Konda S; Takatsuki K; Ichimaru M; Ogawa M; Kimura I; Tominaga S
    J Clin Oncol; 1988 Jan; 6(1):128-41. PubMed ID: 2891797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M).
    Shimoyama M; Ota K; Kikuchi M; Yunoki K; Konda S; Takatsuki K; Ogawa M; Tominaga S; Tsugane S; Minato K
    Jpn J Clin Oncol; 1988 Jun; 18(2):113-24. PubMed ID: 3379782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, prednisolone (VEPA) in non-Hodgkin's lymphoma, with special reference to correlation of surface phenotype with response and survival].
    Chubachi A; Miura AB; Yamaguchi A; Nishimura S
    Gan To Kagaku Ryoho; 1988 Jul; 15(7):2057-63. PubMed ID: 3293535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A comparative study of VEPA and ACOMEP-BD regimen for the patients with non-Hodgkin's lymphoma].
    Kanamori H; Tanabe J; Okamoto R; Tamura T; Fujita H; Murata T; Hashimoto Y; Harano H; Matsuzaki M; Motomura S
    Rinsho Ketsueki; 1993 Jun; 34(6):697-704. PubMed ID: 8366571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MACOP-B treatment in diffuse large-cell lymphoma: identification of prognostic groups in an Italian multicenter study.
    Vitolo U; Bertini M; Brusamolino E; Cavallero GB; Comotti B; Gallo E; Ghio R; Levis A; Luxi G; Meneghini V
    J Clin Oncol; 1992 Feb; 10(2):219-27. PubMed ID: 1370690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A follow-up of a randomized study comparing two chemotherapy treatments for advanced diffuse histiocytic lymphoma.
    Todd M; Cadman E; Spiro P; Bertino J; Farber L; Waldron J; Fischer D
    J Clin Oncol; 1984 Sep; 2(9):986-93. PubMed ID: 6206207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.
    Murakami S; Kato H; Higuchi Y; Yamamoto K; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
    Ann Hematol; 2016 Aug; 95(8):1259-69. PubMed ID: 27220639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
    Sonneveld P; de Ridder M; van der Lelie H; Nieuwenhuis K; Schouten H; Mulder A; van Reijswoud I; Hop W; Lowenberg B
    J Clin Oncol; 1995 Oct; 13(10):2530-9. PubMed ID: 7595704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
    Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.
    Coiffier B; Gisselbrecht C; Vose JM; Tilly H; Herbrecht R; Bosly A; Armitage JO
    J Clin Oncol; 1991 Feb; 9(2):211-9. PubMed ID: 1703226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of primary mediastinal large B-cell lymphomas].
    Schneider T; Tóth E; Molnár Z; Várady E; Deák B; Horváth A; Horváth GI; Eid H; Schneider K; Lovey J; Keresztes S; Esik O; Lengyel Z; Rosta A
    Orv Hetil; 2004 Dec; 145(50):2531-7. PubMed ID: 15662753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD.
    Shipp MA; Harrington DP; Klatt MM; Jochelson MS; Pinkus GS; Marshall JL; Rosenthal DS; Skarin AT; Canellos GP
    Ann Intern Med; 1986 Jun; 104(6):757-65. PubMed ID: 2422995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen.
    Shipp MA; Yeap BY; Harrington DP; Klatt MM; Pinkus GS; Jochelson MS; Rosenthal DS; Skarin AT; Canellos GP
    J Clin Oncol; 1990 Jan; 8(1):84-93. PubMed ID: 1688615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
    Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combination chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisolone (VEPA) for non-Hodgkin's lymphoma].
    Saaki A; Yokomatsu Y; Kojima K; Yoshikawa T; Sannomiya Y; Tatsumi J; Hashimoto K; Park K; Kawarabayashi K; Yoshikawa C
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):65-9. PubMed ID: 3753642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience.
    Kwak LW; Wilson M; Weiss LM; Doggett R; Dorfman RF; Warnke RA; Horning SJ
    J Clin Oncol; 1991 Aug; 9(8):1426-31. PubMed ID: 1712837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Low-grade non-Hodgkin's lymphoma: intensive combined chemotherapy].
    Hattori M; Motomura S; Tomita N; Taguchi J; Tanabe J; Sakai R; Fujisawa S; Fukawa H; Kanamori H; Mouri H; Maruta A; Kodama F; Okubo T
    Rinsho Ketsueki; 1996 Feb; 37(2):101-8. PubMed ID: 8852026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.